TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29448265

Group type: EXPERIMENTAL
Intervention: Mini dental implants (MDI)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard-size implants (SSI)
Number of subjects: 42
Study: 27209300

Group type: EXPERIMENTAL
Intervention: Transabdominal ultrasound at time 0
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Transabdominal ultrasound at 60 minutes
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Transabdominal ultrasound at 90 minutes
Number of subjects: 20
Study: 24570078

Group type: EXPERIMENTAL
Intervention: Nicardipine continuous infusion (0.5 µg/kg per min)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 50
Study: 22435910

Group type: EXPERIMENTAL
Intervention: Web-based TRM intervention
Number of subjects: 8

Group type: COMPARATOR
Intervention: Usual practice (control)
Number of subjects: 8
Study: 20357309

Group type: EXPERIMENTAL
Intervention: Computerised cognitive-behavioural therapy (CCBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CCBT plus TAU
Number of subjects: 0
Study: 18418966

Group type: EXPERIMENTAL
Intervention: Tongguan Capsule (TGC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Western routine therapy with anti-thrombosis and anti-coagulant agents
Number of subjects: 100
Study: 16186280

Group type: EXPERIMENTAL
Intervention: 200 mg vitamin C and 100 IU vitamin E (group V)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Combination of magnesium plus zinc, vitamins C plus E (group MV)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo (group P)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: 200 mg Mg and 30 mg Zn (group M)
Number of subjects: 69
Study: 12639462

Group type: EXPERIMENTAL
Intervention: CCM (cell culture medium supplemented with insulin, thyroxin and growth hormone)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: CCM
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (vehicle)
Number of subjects: 48
Study: 11018196

Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg IR
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Fluvastatin 80 mg ER
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Fluvastatin 160 mg ER
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Fluvastatin ER (all doses)
Number of subjects: 123
Study: 8639252

Group type: COMPARATOR
Intervention: CyA (7 mg/kg per day) and prednisolone
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: CyA (7 mg/kg per day), prednisolone, and oral nifedipine
Number of subjects: 147

Group type: COMPARATOR
Intervention: CyA (4 mg/kg per day), prednisolone, and azathioprine
Number of subjects: 147
Study: 1320241

Group type: EXPERIMENTAL
Intervention: lisinopril
Number of subjects: 52

Group type: COMPARATOR
Intervention: nifedipine
Number of subjects: 52
Study: 30970186

Group type: EXPERIMENTAL
Intervention: Verubecestat 12 mg per day
Number of subjects: 1454

Group type: EXPERIMENTAL
Intervention: Verubecestat 40 mg per day
Number of subjects: 1454

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1454

Group type: EXPERIMENTAL
Intervention: Verubecestat groups
Number of subjects: 1454
Study: 28620677

Group type: EXPERIMENTAL
Intervention: LEB + peloid therapy (5 days a week for 2 weeks)
Number of subjects: 75

Group type: COMPARATOR
Intervention: LEB treatment alone
Number of subjects: 75
Study: 25124939

Group type: EXPERIMENTAL
Intervention: Oleogel‐S10 once daily (n = 53)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Oleogel‐S10 twice daily (n = 51)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo once daily (n = 25)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo twice daily (n = 28)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Overall tolerability of Oleogel‐S10
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Patient-assessed tolerability of Oleogel‐S10
Number of subjects: 165
Study: 22863599

Group type: EXPERIMENTAL
Intervention: Rotigotine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (age-matched)
Number of subjects: 0
Study: 21369817

Group type: EXPERIMENTAL
Intervention: 1-day suprapubic catheterization
Number of subjects: 179

Group type: COMPARATOR
Intervention: 3-day suprapubic catheterization
Number of subjects: 179
Study: 19023654

Group type: EXPERIMENTAL
Intervention: Stepping Stones Triple P
Number of subjects: 59
Study: 17531632

Group type: EXPERIMENTAL
Intervention: Gabexate mesylate 500 mg administered within 1 hour before ERCP (group A, 203 patients)
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Gabexate mesylate 500 mg administered within 1 hour after ERCP (group B, 203 patients)
Number of subjects: 608

Group type: COMPARATOR
Intervention: Saline solution (group C, 202 patients)
Number of subjects: 608
Study: 15206691

Group type: EXPERIMENTAL
Intervention: polyethylene glycol interferon‐ribavirin‐amantadine
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: polyethylene glycol interferon‐ribavirin
Number of subjects: 37
Study: 11468500

Group type: EXPERIMENTAL
Intervention: Autonomy-supportive counseling style
Number of subjects: 249

Group type: COMPARATOR
Intervention: Controlling counseling style
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Both styles
Number of subjects: 249
Study: 10420072

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (dalteparin, Fragmin(R), 10,000 IU s.c. once daily)
Number of subjects: 654

Group type: COMPARATOR
Intervention: Coumarin therapy
Number of subjects: 654
Study: 8306683

Group type: EXPERIMENTAL
Intervention: 50% medium-chain/50% long-chain triglycerides
Number of subjects: 6

Group type: COMPARATOR
Intervention: 100% long-chain triglycerides
Number of subjects: 6
Study: 3189214

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (60,000 micrograms RE)
Number of subjects: 2012

Group type: COMPARATOR
Intervention: Control
Number of subjects: 2012
Study: 29741420

Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic surgery (SILS)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Conventional laparoscopy
Number of subjects: 53
Study: 28339668

Group type: EXPERIMENTAL
Intervention: MCV4 booster dose
Number of subjects: 174
Study: 26296299

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 46

Group type: COMPARATOR
Intervention: Oxygen (control)
Number of subjects: 46
Study: 22882249

Group type: EXPERIMENTAL
Intervention: Insulin aspart (IAsp) 12 IU
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Insulin aspart (IAsp) 24 IU
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Insulin aspart (IAsp) (all doses)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Regular human insulin (RHI) 12 IU
Number of subjects: 16

Group type: COMPARATOR
Intervention: Regular human insulin (RHI) 24 IU
Number of subjects: 16
Study: 21892586

Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum CECT 7315/7316
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19647104

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation for one year
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study: 17958626

Group type: EXPERIMENTAL
Intervention: Triclosan soap
Number of subjects: 224

Group type: COMPARATOR
Intervention: Regular soap (placebo)
Number of subjects: 224
Study: 14706125

Group type: EXPERIMENTAL
Intervention: Megace OS (400 mg daily for 63 days)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Usual NH care
Number of subjects: 17
Study: 11593128

Group type: EXPERIMENTAL
Intervention: Propofol-based anesthetic
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Midazolam, fentanyl, and alfentanil as supplemental agents
Number of subjects: 720
Study: 9159839

Group type: EXPERIMENTAL
Intervention: Continuous Ambulatory Peritoneal Dialysis (CAPD)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Highly Intermittent Peritoneal Dialysis (NIPD)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Both CAPD and NIPD
Number of subjects: 19
Study: 7950196

Group type: EXPERIMENTAL
Intervention: Xinkening
Number of subjects: 31

Group type: COMPARATOR
Intervention: Persantin and Aspirin
Number of subjects: 31
Study: 2888606

Group type: EXPERIMENTAL
Intervention: Systemic Timentin
Number of subjects: 203

Group type: COMPARATOR
Intervention: Oral tinidazole
Number of subjects: 203
Study: 31622389

Group type: EXPERIMENTAL
Intervention: ACP+ program
Number of subjects: 17
Study: 28491234

Group type: EXPERIMENTAL
Intervention: Knowledge on contraception
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Sources of knowledge
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Sexually active students
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Contraceptive utilization
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Age of sexual debut
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Planned sexual debuts
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Age group for sexual debut
Number of subjects: 300
Study: 25329142

Group type: EXPERIMENTAL
Intervention: Injection of triamcinolone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heated lidocaine/tetracaine (Trilexis) patch
Number of subjects: 0
Study: 23361937

Group type: EXPERIMENTAL
Intervention: Cruciate-retaining (CR) TKA
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cruciate-substituting (PS) TKA
Number of subjects: 60
Study: 24590636

Group type: EXPERIMENTAL
Intervention: Yoga (YG)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Stretching (ST)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Waitlist (WL)
Number of subjects: 163
Study: 19998192

Group type: COMPARATOR
Intervention: Active controlled trials (ACTs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo-controlled trials (PCTs)
Number of subjects: 0
Study: 17403837

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 15887218

Group type: EXPERIMENTAL
Intervention: Computed tomography-derived gross tumor volume (GTV) measurements by experienced readers (4 neuroradiologists and 4 radiation oncologists)
Number of subjects: 20
Study: 11793004

Group type: EXPERIMENTAL
Intervention: Prewarmed cotton blankets
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Reflective blanket with head covering over 1 prewarmed cotton blanket
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Forced-warm-air inflatable blanket
Number of subjects: 298

Group type: COMPARATOR
Intervention: Nurses' preference
Number of subjects: 298
Study: 9883300

Group type: EXPERIMENTAL
Intervention: Tri-Nasal Nasal Spray 200 micrograms qd
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Tri-Nasal Nasal Spray 400 micrograms qd
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Nasacort triamcinolone acetonide nasal aerosol 440 micrograms qd
Number of subjects: 377

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 377
Study: 8584771

Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 2213395

Group type: EXPERIMENTAL
Intervention: 400 mg/kg IVIG daily for 4 days
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 1 gm/kg IVIG as a single dose
Number of subjects: 44
Study: 485800

Group type: EXPERIMENTAL
Intervention: Circuit Strength Training (CST)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Jogging
Number of subjects: 16

Group type: COMPARATOR
Intervention: CST or Jogging (final 8 weeks)
Number of subjects: 16
Study: 30417231

Group type: EXPERIMENTAL
Intervention: Bosentan for 12 weeks
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 56
Study: 28385543

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (single doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rosuvastatin with intravenous rifampin (inhibited condition)
Number of subjects: 0
Study: 25281416

Group type: EXPERIMENTAL
Intervention: Laquinimod 0.5 mg/day
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Laquinimod 1.0 mg/day
Number of subjects: 180
Study: 23448846

Group type: EXPERIMENTAL
Intervention: Pharmacological therapy for hypertension
Number of subjects: 6010

Group type: EXPERIMENTAL
Intervention: Demographic factors (male gender, living in a regional area) and clinical factors (history of antihypertensive therapy, increased plasma creatinine, lower pretreatment pulse pressure, in-study use of multiple BP-lowering drugs)
Number of subjects: 6010

Group type: EXPERIMENTAL
Intervention: Seeking care from multiple doctors (aged >80 years)
Number of subjects: 6010
Study: 21562320

Group type: EXPERIMENTAL
Intervention: Unrecognized Q‐wave myocardial infarction at baseline
Number of subjects: 669

Group type: EXPERIMENTAL
Intervention: Unrecognized Q‐wave myocardial infarction at 2 years follow-up
Number of subjects: 669

Group type: EXPERIMENTAL
Intervention: Prevalent myocardial infarctions
Number of subjects: 669

Group type: EXPERIMENTAL
Intervention: Incident myocardial infarctions
Number of subjects: 669
Study: 19748297

Group type: EXPERIMENTAL
Intervention: IRM
Number of subjects: 139

Group type: COMPARATOR
Intervention: Thermoplasticized gutta-percha with AH Plus sealer
Number of subjects: 139
Study: 17012426

Group type: EXPERIMENTAL
Intervention: External fixation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sliding hip screw
Number of subjects: 0
Study: 15290658

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg (n = 5068)
Number of subjects: 11945

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg (n = 1243)
Number of subjects: 11945

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg (n = 3018)
Number of subjects: 11945

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg (n = 2616)
Number of subjects: 11945

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor (PPI) therapy
Number of subjects: 11945

Group type: EXPERIMENTAL
Intervention: Persistent dysphagia (17% of patients)
Number of subjects: 11945
Study: 12536732

Group type: EXPERIMENTAL
Intervention: Intraoperative application of mitomycin C (MMC) 0.4 mg/ml for 1 minute
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no MMC)
Number of subjects: 62
Study: 9678108

Group type: EXPERIMENTAL
Intervention: Monophasic OCs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triphasic OCs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desogestrel-containing OCs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triphasic levonorgestrel/ethinylestradiol and triphasic norgestimate/ethinylestradiol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral contraceptives (all preparations)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral contraceptives (desogestrel/ethinylestradiol 150/20)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (non-users)
Number of subjects: 0
Study: 8382162

Group type: EXPERIMENTAL
Intervention: S (+) oxaprotiline CGP 12,104 A
Number of subjects: 0

Group type: COMPARATOR
Intervention: alpha 2-adrenoceptor binding on intact human platelets
Number of subjects: 0
Study: 3549413

Group type: EXPERIMENTAL
Intervention: Propranolol (doses that reduced resting heart rate by 25%)
Number of subjects: 99

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Propranolol (for compliant patients)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Propranolol (for Child's grade A patients)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 99
Study: 29155195

Group type: EXPERIMENTAL
Intervention: CDDU + ICI (10 µg alprostadil) repeated assessments (maximum of 3 rounds)
Number of subjects: 302

Group type: COMPARATOR
Intervention: CDDU + ICI (10 µg alprostadil) before and after sexological counseling
Number of subjects: 302
Study: 27581473

Group type: EXPERIMENTAL
Intervention: Dietary and physical activity intervention based on Finnish nutrition and physical activity recommendations
Number of subjects: 506

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 506
Study: 25050884

Group type: EXPERIMENTAL
Intervention: Office systolic BP (SBP)
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: 24-h SBP
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: Office diastolic BP (DBP)
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: 24-h DBP
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: Day SBP
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: Office SBP
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: Day DBP
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: Office-day BP (SBP)
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: Office-day BP (DBP)
Number of subjects: 592
Study: 23333252

Group type: EXPERIMENTAL
Intervention: alpha‐methyl‐paratyrosine (AMPT)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 21453791

Group type: EXPERIMENTAL
Intervention: Keep It Off phone-based intervention focusing on weight-loss maintenance behaviors, including self-monitoring, weight reporting, feedback, and outreach.
Number of subjects: 0
Study: 18638651

Group type: EXPERIMENTAL
Intervention: Patients with borderline personality disorder (BPD) with a history of high lethality suicide attempts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with borderline personality disorder (BPD) with a history of low lethality suicide attempts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emergency management approach for patients with BPD presenting with increased risk of suicide
Number of subjects: 0
Study: 16930101

Group type: EXPERIMENTAL
Intervention: Oral melatonin (3mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 12567389

Group type: EXPERIMENTAL
Intervention: Standard postural drainage chest physiotherapy (SPT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Modified physiotherapy regimen without head-down tilt (MPT)
Number of subjects: 20
Study: 10680790

Group type: EXPERIMENTAL
Intervention: 3,4-diaminopyridine (DAP), 20 mg three times daily for 6 days
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 9375332

Group type: EXPERIMENTAL
Intervention: Forced-air warming
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Inhalation rewarming with saturated air at approximately 43 degrees C
Number of subjects: 8

Group type: COMPARATOR
Intervention: Spontaneous rewarming (control)
Number of subjects: 8
Study: 7654578

Group type: EXPERIMENTAL
Intervention: Amorolfine spray 0.5%
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Amorolfine spray 2%
Number of subjects: 382

Group type: COMPARATOR
Intervention: Amorolfine cream 0.5%
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Amorolfine spray (both concentrations)
Number of subjects: 382
Study: 3300174

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion therapy (CSII)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional insulin therapy (CIT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Declined pump treatment
Number of subjects: 40
Study: 29784057

Group type: EXPERIMENTAL
Intervention: Norepinephrine (NE) tapering first
Number of subjects: 78

Group type: COMPARATOR
Intervention: Vasopressin (AVP) tapering first
Number of subjects: 78
Study: 27211885

Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.2%
Number of subjects: 78

Group type: COMPARATOR
Intervention: Routine oral care with thymol
Number of subjects: 78
Study: 24328800

Group type: EXPERIMENTAL
Intervention: Self-reported MHI
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Loss of consciousness (within MHI)
Number of subjects: 91

Group type: COMPARATOR
Intervention: No-MHI
Number of subjects: 91
Study: 23539700

Group type: EXPERIMENTAL
Intervention: Mobile bearings
Number of subjects: 539

Group type: COMPARATOR
Intervention: Fixed bearings
Number of subjects: 539
Study: 20602016

Group type: EXPERIMENTAL
Intervention: 20 mg piroxicam‐beta‐cyclodextrin
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 40 mg piroxicam‐beta‐cyclodextrin
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 18955748

Group type: EXPERIMENTAL
Intervention: Mid drive-axis wheelchair
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Rear drive-axis wheelchair
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Using arms and legs simultaneously
Number of subjects: 16

Group type: COMPARATOR
Intervention: Front drive-axis wheelchair
Number of subjects: 16

Group type: COMPARATOR
Intervention: Using arms only
Number of subjects: 16

Group type: COMPARATOR
Intervention: Using legs only
Number of subjects: 16
Study: 17140945

Group type: EXPERIMENTAL
Intervention: Dilutional conventional ultrafiltration (group D)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Modified ultrafiltration (group M)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both dilutional conventional and modified ultrafiltration (group B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 60
Study: 12689799

Group type: EXPERIMENTAL
Intervention: Combined Pap smear plus mammogram reminders
Number of subjects: 2471

Group type: COMPARATOR
Intervention: Mammogram-only reminders
Number of subjects: 2471
Study: 10325852

Group type: EXPERIMENTAL
Intervention: Carbon dioxide pneumoperitoneum
Number of subjects: 28

Group type: COMPARATOR
Intervention: Abdominal wall lifting
Number of subjects: 28

Group type: COMPARATOR
Intervention: Laparoscopic appendectomy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Open appendectomy
Number of subjects: 28
Study: 8523135

Group type: EXPERIMENTAL
Intervention: V/Q lung scan interpreted as normal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: V/Q lung scan interpreted as very low, low, or high probability of PE
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: V/Q lung scan interpreted as intermediate probability of PE
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: V/Q lung scan with discordant clinical likelihood of PE
Number of subjects: 0
Study: 1952847

Group type: EXPERIMENTAL
Intervention: Temafloxacin hydrochloride (400 mg once a day for 7 days)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Trimethoprim (160 mg) and sulfamethoxazole (800 mg) (TMP-SMZ) twice daily for 10 days
Number of subjects: 400
Study: 7026971

Group type: EXPERIMENTAL
Intervention: Methandrostenolone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30368852

Group type: EXPERIMENTAL
Intervention: Family therapy
Number of subjects: 183

Group type: COMPARATOR
Intervention: Individual treatment
Number of subjects: 183